These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24266815)

  • 1. Biomarkers to guide therapy or surveillance for prostate cancer.
    Citrin D; Hudak K; Camphausen KA
    Biomark Med; 2013 Dec; 7(6):827-9. PubMed ID: 24266815
    [No Abstract]   [Full Text] [Related]  

  • 2. Contemporary role of prostate cancer gene 3 in the management of prostate cancer.
    Roobol MJ
    Curr Opin Urol; 2011 May; 21(3):225-9. PubMed ID: 21301341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dilemma of prostate-specific antigen testing.
    Leach R; Thompson IM
    Arch Intern Med; 2012 Jun; 172(11):835-6. PubMed ID: 22905350
    [No Abstract]   [Full Text] [Related]  

  • 4. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial and introduction to Asian Journal of Andrology Prostate Cancer special issue.
    Kirby R; Xia SJ
    Asian J Androl; 2009 Jan; 11(1):6-8. PubMed ID: 19098933
    [No Abstract]   [Full Text] [Related]  

  • 6. New tests for prostate cancer.
    O'Hanlon LH
    J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330
    [No Abstract]   [Full Text] [Related]  

  • 7. Rising PSA level in a 46-year-old man.
    Crawford ED
    Oncology (Williston Park); 2013 May; 27(5):394, 478. PubMed ID: 25184261
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
    Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
    Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: Improving early detection--can PCA3 do more?
    Phillips R
    Nat Rev Urol; 2015 Jan; 12(1):1. PubMed ID: 25420437
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
    Taneja SS
    J Urol; 2015 Jul; 194(1):115. PubMed ID: 26088225
    [No Abstract]   [Full Text] [Related]  

  • 12. Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation.
    Vickers AJ
    J Clin Oncol; 2014 Dec; 32(36):4033-4. PubMed ID: 25366689
    [No Abstract]   [Full Text] [Related]  

  • 13. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis: Proportionate response.
    DeWeerdt S
    Nature; 2015 Dec; 528(7582):S124-5. PubMed ID: 26672783
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
    DiPaola RS; Chenven ES; Shih WJ; Lin Y; Amenta P; Goodin S; Shumate A; Capanna T; Cardiella M; Cummings KB; Aisner J; Todd MB
    Cancer; 2001 Oct; 92(8):2065-71. PubMed ID: 11596021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The new biomarkers of prostate cancer].
    Bessede T; Malavaud B
    Prog Urol; 2011 Mar; 21 Suppl 2():S63-7. PubMed ID: 21397832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel prostate cancer antigen 3 (PCA3) biomarker.
    Bourdoumis A; Papatsoris AG; Chrisofos M; Efstathiou E; Skolarikos A; Deliveliotis C
    Int Braz J Urol; 2010; 36(6):665-8; discussion 669. PubMed ID: 21176272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comments on the article "Biomarkers for prostate cancer" by Eric Schiffer.
    Marshall S
    World J Urol; 2009 Aug; 27(4):577-8. PubMed ID: 19543735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.